Abstract: The invention relates to the production of new Plasmodium mutants which are defective in the expression of the protein P36p. These mutants are unable to cause malaria, yet they can be used as vaccine, giving long lasting protection against infections with wild-type Plasmodium.

Abstract: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candidaalbicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind Candida albicans both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize Candida in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another Candida receptor on DC. Together, these results demonstrate that C. albicans has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.

Abstract: The invention is related to a method for generating hardness and/or strain information of a tissue which can be subject to a varying pressure, the method comprising: —positioning at least one signal transmitter (1) outside the tissue (10); —positioning at least one signal receiver (1) outside the tissue (10); —using the signal transmitter (1) to send signals (S) at different angles towards the tissue; —using the signal receiver (1) to receive signals from the tissue (10), wherein the received signals result from the signals that have been sent by said signal transmitter. The invention is also related to an apparatus for carrying out the method.

Abstract: The invention relates to a process for the biological treatment of ammonium-rich aqueous media in the presence of ammonia oxidizing bacteria, by supplying nitrogen dioxide (NO2) into said aqueous media, thus effecting a nitrification and a denitrification, wherein further nitrogen oxide (NO) is supplied into said media such that the ratio of NO:NO2 is in the range from 1:2 to 1:500 (v/v). Further the use of off-gases in this process is disclosed as well as microorganisms cultured in the presence of NO and NO2.

Abstract: This invention describes the cloning and characterization of the promoter region for the PCA3dd3 gene. This region regulates the PCA3dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.

Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

Abstract: This invention describes the cloning and characterization of the promoter region for the PCA3dd3 gene. This region regulates the PCA3dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.

Abstract: This invention describes the cloning and characterization of the promoter region for the PCA3dd3 gene. This region regulates the PCA3dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.

Abstract: A measuring device for measuring the intensity and/or polarization of electromagnetic radiation, more in particular of light. The measuring device is provided with a tunnel tip arranged facing a body at some distance, which tunnel tip at least partly consists of a semiconductor material. The measuring device further comprises a control unit for obtaining information about the intensity and/or polarization of the radiation by means of a tunnel current, generated under the influence of the radiation in the tunnel tip, between the tunnel tip and the body and/or a surface photovoltage of the tunnel tip, generated under the influence of the radiation.

Abstract: Monamine oxidase genes and proteins associated with abnormal behavior are provided. Cells and non-human transgenic animals comprising at least one mutant monamine oxidase gene, and purified mutant monamine oxidase protein are also provided. The genes, cells and proteins of the invention are useful in the and therapeutic and diagnostic methods provided which relate to treating and diagnosing individuals having a mutant monamine oxidase gene and exhibiting an associated abnormal behavior.

Abstract: In order, in the epitaxial production of semiconductor products and of articles provided with a layer, to be able to make the junction between the layers applied to the substrates atomically sharp, it is important to be able to change the gas mixture, to be introduced into a pulsed reactor or MBE reactor, rapidly, accurately and without losses in respect of quantity and of composition. To this purpose, each of the gases to be introduced into the reactor is conveyed to a separate gas pipette and thereafter the content of the gas pipette is cyclically passed, by means of a pressure differential, into the pulse reactor, with the composition of the mixture being changed per one or more cycles.

Abstract: The invention relates to novel sparsomycin (S.sub.c -R.sub.s) compounds having valuable antitumor activity, and to a process for their preparation and pharmaceutical compositions containing such novel compounds.

Abstract: The invention relates to phosphorylating agents containing at least one protected hydroxyl group and at least one leaving group. According to the invention, a methylsulphonylethyl group (Mse) is used as the hydroxyl protecting group. Typical examples of such phosphorylating agents are the compounds (MseO).sub.2 POL, (MseO)POLL', (MseO).sub.2 PL and (MseO)PLL', in which L and L' are leaving groups. The invention also relates to processes for preparing these phosphorylating agents and processes for the phosphorylation of organic hydroxyl or amine compounds, in particular nucleosides and (poly)nucleotides.

Abstract: The invention concerns novel sparsomycin (S.sub.c -R.sub.s) derivatives having superior cytostatic activity compared to sparsomycin itself. Said derivatives contain a lipophilic group R.sup.2, selected from C.sub.2 -C.sub.20 -alkyl, aryl, aralkyl and alkaryl, which is preferably n-octyl or benzyl.